What Is a 340B Pharmacy? A Practical Guide to Eligibility and Access

Hospitals, FQHCs, and other safety-net providers register with HRSA and then route outpatient prescription purchases through either an in-house dispensary or a contract partner that buys at federally mandated ceiling prices. The discount is invisible at the counter for most patients, but it quietly frees up real money inside hospitals, community health centers, and HIV/AIDS clinics serving low-income populations.

The 340B pharmacy program was created in 1992 to help these safety-net providers stretch limited federal resources, not to subsidize individual prescriptions, and that distinction shapes every rule that follows.

This guide explains how the 340B pharmacy program works, who qualifies as a covered entity, and what compliance really looks like day to day. It covers the mechanics, the patient experience, and the reform debates shaping the program’s future.

The Origins and Purpose of the 340B Drug Pricing Program

Congress added Section 340B to the Public Health Service Act in 1992, and the law has shaped drug pricing for safety-net providers ever since. The statute requires pharmaceutical manufacturers that want to participate in Medicaid to offer outpatient drugs at ceiling prices to a defined set of “covered entities.” Without that requirement, manufacturers would have little reason to extend deeper discounts to hospitals and clinics that serve a disproportionate share of uninsured and underinsured patients.

The legislative language matters here. Lawmakers chose to help safety-net providers “stretch scarce federal resources” rather than subsidize drugs directly. That phrasing means the savings belong to the entity, not the patient, and it gives covered entities wide latitude to reinvest the difference into the services their communities actually need.

Where 340B Fits in U.S. Drug Pricing

The 340B program sits alongside Medicare Part B reimbursement and the Medicaid Drug Rebate Program as one of three pillars of federal pharmaceutical policy. Each works differently. Medicare Part B pays providers for drugs administered in clinical settings. The Medicaid Drug Rebate Program requires manufacturers to pay rebates on drugs already dispensed to Medicaid enrollees.

The 340B pharmacy program, by contrast, gives covered entities an upfront ceiling-price discount at the point of purchase, which can average 25 to 50 percent off a drug’s average manufacturer price according to HRSA estimates.

That discount only reaches patients, though, when a hospital or clinic qualifies for the program in the first place.

Who Qualifies as a Covered Entity Under 340B

HRSA, the Health Resources and Services Administration, administers the 340B pharmacy program and decides which organizations qualify. The agency groups covered entities into six statutory categories, each with its own eligibility test and its own recertification cycle. Missing a recertification deadline can terminate participation, and rejoining the program is not automatic.

The Six Statutory Categories at a Glance

CategoryExamplesEligibility Anchor
Federally qualified health centers (FQHCs)Community health centers, migrant health centers, health care for the homeless granteesFederal grant funding under Section 330 of the Public Health Service Act
Ryan White HIV/AIDS Program granteesState and local HIV care and treatment providersActive Ryan White grant award
Title X family planning clinicsPublic and nonprofit family planning networksTitle X grant funding
Disproportionate share hospitals (DSH)Large urban and rural acute-care hospitalsMedicare DSH adjustment and state Medicaid metrics
Children’s hospitalsFree-standing pediatric hospitalsMedicare-defined children’s hospital criteria
Free-standing cancer hospitalsIndependent cancer treatment centersSpecialized cancer hospital designation

Annual recertification through the HRSA 340B Office of Pharmacy Affairs is required for every category. A covered entity that fails to recertify is removed from the program, and 340B drug purchases made after termination can trigger repayment obligations and referral to the Office of Inspector General for further review.

How a Pharmacy Becomes a 340B Pharmacy

Qualifying hinges less on a single application form and more on a documented relationship between a covered entity and a dispensing pharmacy. Either a covered entity operates its own in-house pharmacy, or it partners with an outside retail or mail-order pharmacy that agrees to dispense on the entity’s behalf under a written contract pharmacy arrangement. The pharmacy itself does not “qualify” the way a hospital does.

The covered entity holds the enrollment, and the pharmacy rides on that enrollment through a contractual link.

In-House Pharmacies and Contract Pharmacies

An in-house pharmacy is owned and operated by the covered entity, dispenses 340B drugs directly to eligible patients, and keeps the entity in full control of inventory, software, and recordkeeping. A contract pharmacy arrangement, by contrast, lets a covered entity extend its 340B reach to retail chains, independent pharmacies, and mail-order providers without building a new dispensary.

Each contract pharmacy must be registered with HRSA, and each covered entity is responsible for vetting the partner’s compliance program before any 340B prescriptions are filled.

Contract pharmacy requirements include a written agreement, registration in the HRSA 340B Office of Pharmacy Affairs database, and ongoing monitoring of the partner’s claims, inventory, and audit trail. The contract pharmacy is paid for its dispensing services, and the covered entity retains the 340B savings on the drug itself.

Software, Vendors, and Prime Vendor Pricing

Most 340B pharmacies rely on a third-party administrator and split-billing software to track which prescriptions qualify as 340B and which do not. The software pulls data from the pharmacy’s dispensing system, checks each claim against the covered entity’s patient definition, and routes qualifying claims to a separate 340B inventory account in real time.

Apexus, the program’s prime vendor, sits at the center of this infrastructure by negotiating sub-ceiling pricing and distribution agreements that help covered entities buy below the statutory 340B ceiling.

Once a pharmacy clears those structural hurdles, attention shifts to the daily workflows that keep everything auditable.

Inside the Day-to-Day Operations of a 340B Pharmacy

A registered pharmacist or an authorized employee under pharmacist oversight verifies three things before a prescription can be filled under 340B: that the patient has a documented relationship with the covered entity, that a provider employed or contracted by the entity wrote the prescription, and that the service date falls within an active care episode. If any of those three checks fail, the prescription drops to standard commercial pricing.

Inventory Models and Duplicate-Discount Prevention

Inventory handling varies across 340B pharmacy sites. Some use a virtual replenishment model, where the pharmacy orders replacement 340B stock only after a qualifying claim is processed, and others maintain a physical 340B-only stock physically separated from the rest of the dispensary. Either model works, but each demands audit-ready records that can be reconstructed on demand during an HRSA review.

Heads up: Duplicate-discount prevention is the single most common compliance failure in 340B pharmacy program. Covered entities must coordinate with state Medicaid agencies on a carve-in or carve-out decision for each drug, and a mismatch between the HRSA Medicaid exclusion file and the state claim can trigger repayment on every overlapping fill.

Apexus extends its role well past price negotiation. The prime vendor runs compliance support, the 340B University training program for new staff, and peer learning networks that help smaller covered entities keep pace with the program’s evolving audit standards.

What Patients Experience at a 340B Pharmacy

From the patient’s perspective, a 340B pharmacy visit looks almost identical to any other pharmacy encounter. The discount mechanics stay largely invisible at the counter, and the pharmacist’s workflow mirrors the one used for any commercial fill. The differences show up behind the scenes, in the billing and inventory systems, not in the waiting area.

Eligibility, Copays, and Reinvestment

Eligibility for a 340B fill requires a documented relationship with the covered entity and care provided by a provider employed or contracted by that entity. A patient who walks into a contract pharmacy with an outside prescription, even if they qualify for charity care elsewhere, cannot have that prescription filled under 340B. The pharmacy must have the entity’s care encounter in its records before the claim can be tagged.

Patients may receive reduced copays, free medications, or expanded clinical services funded by 340B savings, depending on how the covered entity chooses to reinvest the margin. Federal law leaves that decision to the entity, which has fueled both innovation in community health and ongoing debate about transparency. Savings are unrestricted by the statute, but they must support the entity’s mission to serve low-income patients, and that broad mandate has become one of the most contested parts of the program.

Compliance Risks, Audits, and the Road Ahead for 340B

HRSA audits have grown more frequent and more pointed over the last several years. The most common findings involve patient-definition errors, duplicate discounts, and contract pharmacy recordkeeping. A single finding can result in repayment to manufacturers, termination from the program, and referral to the Office of Inspector General. For smaller covered entities, the cost of a failed audit often outweighs the savings the program was meant to deliver.

Manufacturer Penalties and Reform Debates

Manufacturers that refuse to honor 340B pricing face civil monetary penalties and potential termination from federal healthcare programs, including Medicaid and Medicare. Several manufacturers have pushed back on contract pharmacy arrangements in recent years, arguing that the statute does not require them to ship discounted drugs through unlimited external dispensaries. That legal fight is still working its way through the courts, and the outcome could reshape how 340B pharmacy contract pharmacy arrangements operate.

Reform debates also focus on DSH hospital participation, the rapid growth of contract pharmacy proliferation, and the absence of federal reporting on how covered entities actually spend their 340B savings. Comparing 340B with the Medicaid Drug Rebate Program clarifies the structural difference. The Medicaid Drug Rebate Program pays rebates on drugs already purchased, while 340B delivers an upfront ceiling-price discount at the moment of purchase, and the two streams must be kept cleanly separated to avoid duplicate discounts.

Bottom Line

Federal statute requires manufacturers to offer ceiling-price outpatient drugs to enrolled safety-net providers, who then channel the margin back into care for low-income patients. Eligibility, recertification, and audit readiness are the operational reality, and the patient experience is shaped more by each covered entity’s mission than by any federal mandate on copays.

FAQ

What is a 340B pharmacy and how does it work?

Enrolled safety-net providers purchase outpatient drugs at ceiling prices set by the federal program and redeploy the savings toward services for underserved patients. Either the covered entity operates the pharmacy directly, or a contract pharmacy partner dispenses on the entity’s behalf through a written agreement.

Who qualifies as a covered entity under the 340B program?

HRSA recognizes six categories of covered entities, including FQHCs, Ryan White HIV/AIDS Program grantees, Title X family planning clinics, DSH hospitals, children’s hospitals, and free-standing cancer hospitals. Each category has its own statutory test and an annual recertification requirement.

How does a pharmacy become a 340B pharmacy?

The covered entity enrolls in the program through HRSA, then either opens its own in-house pharmacy or signs a written contract pharmacy agreement with an external retail or mail-order pharmacy. The contract pharmacy is registered with HRSA, and split-billing software tracks which claims qualify as 340B.

What is the difference between 340B and regular pharmacy pricing?

Commercial contracts between pharmacies, manufacturers, and wholesalers set usual market prices, whereas a separate federal ceiling-price formula governs what enrolled covered entities pay for the same drugs. The 340B discount can average 25 to 50 percent off the average manufacturer price, and the savings belong to the covered entity, not the patient.

What are the requirements for a 340B contract pharmacy?

Written agreements with a covered entity, HRSA registration, patient-definition audits, Medicaid duplicate-discount safeguards, and audit-ready fill records are the five compliance pillars every contract pharmacy must maintain.

Staff
Staff

Our team brings together health and food enthusiasts who are passionate about discovering reliable health information, nutritious choices, and enjoyable food experiences. From everyday nutrition and healthy eating ideas to recipes, ingredients, food trends, and standout dishes, we share carefully researched and thoughtfully curated content to help readers make informed choices about what they eat and enjoy.